MRK Merck & Co. Inc.

Merck Foundation Grant Expands YMCA’s Diabetes Prevention Program in Five States

The Merck Foundation and YMCA of the USA (Y-USA) announced today that the Merck Foundation has provided a grant of $2 million over three years to support efforts to expand the YMCA’s Diabetes Prevention Program (YMCA’s DPP). This evidence-based, chronic disease prevention program aims to improve the health of participants with prediabetes through modest weight loss achieved by healthy eating and physical activity. The grant supports the program’s expansion in 60 communities across five states – Illinois, Kentucky, New Jersey, Pennsylvania and Texas.

The YMCA’s DPP, part of the National Diabetes Prevention Program led by the U.S. Centers for Disease Control and Prevention (CDC), is a lifestyle behavior intervention program that includes 25 sessions delivered over 12 months in a small group setting. Programs like the YMCA’s DPP have shown a 58- to 71-percent reduction in the prevention or delay of new cases of type 2 diabetes in adults over 60.

“Diabetes is a serious and growing public health issue in the United States, and people with prediabetes have an increased chance of developing type 2 diabetes, heart disease and stroke. Community-based, lifestyle intervention programs, like the YMCA’s DPP, address health care gaps to help those at risk make changes to improve their health,” said Dr. Julie L. Gerberding, chief patient officer, Merck and chief executive officer, Merck Foundation. “We are proud to partner with the Y-USA to implement innovative and highly effective approaches to prevent type 2 diabetes.”

According to the CDC, an estimated 29 million people are living with diabetes in the United States. Additionally, 15 to 30 percent of the estimated 86 million people with prediabetes will develop type 2 diabetes within five years unless they make changes to improve their health.

“We are honored to partner with the Merck Foundation to address the rising diabetes epidemic which costs the nation $245 billion annually,” said Dr. Matt Longjohn, national health officer, Y-USA. “As one of the leading community-based charities committed to improving America’s health, this grant will extend the Y’s reach and help reduce health disparities in five states with high rates of type 2 diabetes.”

The YMCA’s DPP in Illinois, Kentucky, New Jersey, Pennsylvania and Texas, will receive funding over three years to establish community outreach programs, and will source local funders and payors, as well as establish partnerships to ensure the program becomes embedded into the local communities for long-term success.

Participants in the expanded program will have the opportunity to join more than 46,000 peers and 4,000 health coaches in existing networks across 47 states – amounting to the largest in-person delivery of quality interventions in the United States.

About the Y

The Y is one of the nation’s leading nonprofits strengthening communities through youth development, healthy living and social responsibility. In the United States, 2,700 Ys engage 22 million men, women and children – regardless of age, income or background – to nurture the potential of children and teens, improve the nation’s health and well-being, and provide opportunities to give back and support neighbors. Anchored in more than 10,000 communities, the Y has the long-standing relationships and physical presence not just to promise, but to deliver, lasting personal and social change. For more information, visit www.ymca.net.

About the Merck Foundation

The Merck Foundation is a U.S.-based, private charitable foundation. Established in 1957 by Merck, a global health care leader, the Foundation is funded entirely by the company and is Merck’s chief source of funding support to qualified non-profit charitable organizations. Since its inception, the Merck Foundation has contributed more than $844 million to support important initiatives that address societal needs and are consistent with Merck’s overall mission to help the world be well. For more information, visit www.merckgiving.com.

EN
29/09/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Merck & Co. Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Coasting as We Stalk for Buying Opportunity; Downgrading Discretionary to Underweight We had been near-term bullish on the S&P 500 (SPX) since our 4/22/25 Compass, however, we are officially downgrading our near-term outlook to neutral. The SPX, Nasdaq 100 (QQQ), and Russell 2000 (IWM) are breaking below their 50-day MAs and are also violating their multi-month uptrends, signaling a consolidation period is here. With that said, our intermediate-term outlook remains bullish (as of our 5/14/25 Co...

Merck & Co Inc: 1 director

A director at Merck & Co Inc sold 7,085 shares at 87.000USD and the significance rating of the trade was 94/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...

Research Team ACF
  • Research Team ACF

ACF Thematic Oncology Lung Cancer Cough LCC 25042025

Lung Cancer Cough (LCC) is an under-served, perhaps unserved therapeutic subsegment of the Lung Cancer/Oncology market. 57-65% of early diagnosis lung cancer patients suffer from LCC, it is a highly debilitating condition. The US lung cancer therapeutics market consensus values range from ~USD 29.9bn in 2023 to ~USD 71.3bn in 2034, suggesting a compound annual growth rate (CAGR) of 8.2% over our 10 year forecast period. LCC is a prevalent symptom among lung cancer patients, and its management is...

Research Team ACF
  • Research Team ACF

Regenerative Healthcare - Stem Cells & ALS Thematic 10062024

Regenerative medicine remains an extremely exciting area of healthcare with vast investment potential. In spite of the usual setbacks in valuation and strategy, the sub-sector has pivoted and the market remains innovative and attracts investment capital. Rather than replace entire tissues, which is a complex activity, we believe the immediate future for stem cells is more likely to be in the successful stimulation of the bodies on repair mechanisms. Within regenerative medicine we believe there ...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch